Does Isturisa’s patent expire in the EU?
“Isturisa” is the brand name for osilodrostat (for Cushing’s disease). Patent expiry in the EU depends on the specific patent(s) covering the product and whether any extensions or supplementary protections apply. Without the exact patent numbers (or the specific form such as the marketing authorization/paediatric/market exclusivity context), you can’t determine one single “EU expiry date” from the brand name alone.
What determines the EU “patent expiry” date for Isturisa?
EU timelines usually come from multiple layers that can all get described as “expiry,” including:
- The last day a relevant patent (covering the drug substance, formulation, or method of use) is enforceable in Europe.
- Any patent term extensions or related protections available under EU/EEA rules (varies by case).
- Regulatory exclusivities (these are not patents, but they often affect when competitors can launch).
Because “patent expiry” and “market entry/launch availability” are different concepts, the earliest possible launch timing for a competitor is often governed by a mix of patent status and regulatory exclusivity.
How can you find the exact Isturisa patent expiry for the EU?
To get the correct EU expiry, you need to look up:
- The key European patents for osilodrostat (via the European Patent Register / Espacenet), and identify which ones are in force for the relevant countries (including EU member states).
- The national status in each country (patents can lapse or differ by territory).
- Any supplementary protection related data (if applicable) and the marketing authorization date context used for extensions/exclusivity.
If you tell me the country (or patent number), can you narrow it to a date?
Yes. If you share either:
- the EU country you care about (e.g., France, Germany, Spain, UK vs EU), or
- the European patent number(s) you’re asking about, or
- the marketing authorization number,
I can help map that to the relevant expiry concepts and the most likely “last enforceable date” versus “earliest launch” in that jurisdiction.
Sources: none provided.